Related MeSH Hierarchy (4)
Diseases [C] » Digestive System Diseases [C06] » Pancreatic Diseases » Cystic Fibrosis
Diseases [C] » Respiratory Tract Diseases [C08] » Lung Diseases » Cystic Fibrosis
Diseases [C] » Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] » Genetic Diseases, Inborn » Cystic Fibrosis
Diseases [C] » Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] » Infant, Newborn, Diseases » Cystic Fibrosis
Description
An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. MeSH
Hierarchy View
Phase 4 Indicated Drugs (46)
Phase 3 Indicated Drugs (25)
Phase 2 Indicated Drugs (93)
Other Experimental Indicated Drugs (45)
Organization Involved with Phase 4 Indications (72)
Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
Canadian Cystic Fibrosis Foundation
CF Therapeutics Development Network Coordinating Center
Cystic Fibrosis Foundation Therapeutics
Katholieke Universiteit Leuven
Medical College and Hospital Kolkata
National Heart, Lung, and Blood Institute (NHLBI)
The Physicians' Services Incorporated Foundation
The University of Texas, Dallas
Universidad Complutense de Madrid
University of Alabama, Birmingham
Organization Involved with Phase 3 Indications (71)
AmpliPhi Biosciences Corporation
Case Western Reserve University
Centre Hospitalier Intercommunal Creteil
European Cystic Fibrosis Society-Clinical Trial Network
Fondazione per la ricerca sulla Fibrosi Cistica
Klinika Pneumonologii i Mukowiscydozy, Instytut Gruzlicy i Chorob Pluc w Rabce Zdroj
National Health and Medical Research Council, Australia
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Organization Involved with Phase 2 Indications (116)
Advanced Inhalation Therapies Ltd
Belgian Society against Cystic Fibrosis
Cook Children's Medical Center
Cyclacel Pharmaceuticals, Inc.
Eastern Virginia Medical School
Epidemiologie Pharmacologie Investigation Clinique Information medicale Mere Enfant
FemmePharma Global Healthcare, Inc.
German Center for Lung Research
Institut National de la Santé Et de la Recherche Médicale, France
Instituto Mexicano del Seguro Social
Instituto Nacional de Enfermedades Respiratorias
Kinderklinik und Kinderpoliklinik im Haunerschen Kinderspital
National Institutes of Health (NIH)
Nordmark Arzneimittel GmbH & Co. KG
Rainbow Baby and Children's Hospital
Smerud Medical Research Denmark
Organization Involved with Phase 1 Indications (38)
Organization Involved with Other Experimental Indications (31)
Assistance Publique - Hôpitaux de Paris
Belgische Vereniging voor Strijd tegen Mucoviscidose
Government of British Columbia
Icahn School of Medicine at Mount Sinai
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
